Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Bisantrene by Race Oncology for Refractory Acute Myeloid Leukemia: Likelihood of Approval
Bisantrene is under clinical development by Race Oncology and currently in Phase II for Refractory Acute Myeloid Leukemia. According to...
Data Insights
Bisantrene by Race Oncology for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
Bisantrene is under clinical development by Race Oncology and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to...